FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

NCT ID: NCT04891757

Last Updated: 2025-07-10

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 144 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-06-14
• Study Completion Date: 2027-06-30

Brief Summary

This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.

Detailed Description

This study is primarily intended to evaluate the safety and tolerability of FHD-286 when administered orally as monotherapy or in combination with either LDAC or decitabine to subjects with R/R AML, R/R MDS, and R/R CMML not in blast crisis. In each arm of the study, successive cohorts of participants will receive increasing oral doses of FHD-286 as a single agent or in combination with LDAC or decitabine to determine the RP2D(s) in this population.

The data from this study in subjects with advanced hematologic malignancies, including safety, tolerability, PK/PD findings, and antitumor activity, will form the basis for subsequent clinical development of FHD-286.

Conditions

Advanced Hematologic Malignancy; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Relapsed Myelodysplastic Syndromes; Refractory Myelodysplastic Syndromes; Relapsed Chronic Myelomonocytic Leukemia; Refractory Chronic Myelomonocytic Leukemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

FHD-286 Monotherapy

Closed to Enrollment

Group Type: EXPERIMENTAL

FHD-286

Intervention Type: DRUG

FHD-286 administered orally

FHD-286 in Combination with LDAC

FHD-286 administered orally + LDAC administered subcutaneously

Group Type: EXPERIMENTAL

FHD-286

Intervention Type: DRUG

FHD-286 administered orally

Low Dose Cytarabine

Intervention Type: DRUG

LDAC administered subcutaneously (SC)

FHD-286 in Combination with Decitabine

FHD-286 administered orally + decitabine administered intravenously (IV)

Group Type: EXPERIMENTAL

FHD-286

Intervention Type: DRUG

FHD-286 administered orally

Decitabine

Intervention Type: DRUG

Decitabine administered intravenously

Interventions

FHD-286

FHD-286 administered orally

Intervention Type: DRUG

Low Dose Cytarabine

LDAC administered subcutaneously (SC)

Intervention Type: DRUG

Decitabine

Decitabine administered intravenously

Intervention Type: DRUG

Other Intervention Names

LDAC

Eligibility Criteria

Inclusion Criteria

1. Subject must be ≥16 years of age.

2. Subject must:

• Have a confirmed diagnosis of R/R AML, R/R MDS, or R/R CMML not in blast crisis AND
• Have received ≤4 prior lines of systemic anticancer therapy for their disease under study; subjects who have received >4 prior lines of systemic anticancer therapy for their disease under study must receive Sponsor approval. AND
• Be an appropriate candidate for treatment with LDAC (Arm A) or decitabine (Arm B)

3. Subject or their parent or legal guardian (when applicable) must be able to understand and be willing to sign an informed consent and, when applicable, subject must sign an assent form.

4. Subject must be willing and able to comply with scheduled study visits and treatment plans.

5. Subject must be willing to undergo all study procedures unless contraindicated due to medical risk.

6. Subject must have an ECOG PS of ≤2.

7. Subject must have a life expectancy of ≥3 months.

8. Subject must have adequate hepatic function.

9. Subject must have adequate renal function.

10. Subject must have a WBC count ≤20×109/L; treatment with a stable dose of hydroxyurea or other cytoreductive agent (eg, cytarabine) to achieve this count is allowed.

11. Subject must have adequate cardiovascular, respiratory, and immune system function.

12. Subject must agree to abide by dietary and other considerations required during the study.

13. Subject must meet timing requirements with respect to prior therapy and surgery

14. Toxicity related to prior therapy must have returned to Grade ≤2 by CTCAE by approximately 14 days before the start of study treatment or be deemed irreversible and stable by the Investigator. Exceptions include alopecia, neuropathy, appropriately controlled endocrine toxicities, and other well-controlled stable toxicities with discussion with the Sponsor.

15. Female subjects must be:

• postmenopausal; or
• permanently sterile, or, if sexually active with male partners, these partners must be azoospermic; or
• nonpregnant, nonlactating, and, if sexually active with fertile male partners, having agreed to use a highly effective method of contraception

16. Male subjects must have documented azoospermia or, if fertile and sexually active, must agree to use a highly effective method of contraception with their partners of childbearing potential

Exclusion Criteria

1. Subject is unable to provide informed consent and/or to follow protocol requirements.

2. Subject:

• Has undergone chimeric antigen receptor T cell therapy or HSCT within 60 days of the first dose of study treatment OR
• Has clinically significant GVHD

3. Subject has evidence (or suspicion) of extramedullary involvement, unless approved by Sponsor.

4. Subject has an immediately life-threatening, severe complication(s) of advanced myeloid malignancy, such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.

5. Subject has other malignancy that may interfere with the diagnosis and/or treatment of advanced hematologic malignancies.

6. Subject has active HBV or HCV infections; Subject has known positive HIV antibody results, or AIDS-related illness.

7. Subject has an active severe infection that requires anti-infective therapy or has an unexplained temperature of >38.5°C during screening visits or on their first day of study treatment.

8. Subject has an uncontrolled intercurrent illness.

9. Subject has QTcF >470 msec or other factors that increase the risk of QTc prolongation or arrhythmic events.

10. Subject has any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent/assent, cooperate, or participate in the study.

11. Subject has known allergies or hypersensitivities to:

• All subjects: components of the FHD-286 formulation
• Arm A: cytarabine or any of the excipients
• Arm B: decitabine or any of the excipients

12. Subject is unable to tolerate the administration of oral medication or has GI dysfunction that would preclude adequate absorption, distribution, metabolism, or excretion of FHD-286.

13. Subject is receiving any other anticancer investigational agents. Investigational agents to treat non-cancer indications may be permitted with Sponsor approval.

15. Subject is on medications classified as:

• Strong CYP3A inhibitors [Exception: Triazole antifungal agents, including those classified as strong CYP3A inhibitors, are permitted.]
• Strong CYP3A inducers
• Sensitive CYP3A substrates with narrow TIs [Stable doses of immunosuppressant medications that are sensitive CYP3A4 substrates may be permitted with Sponsor approval.]

16. Subject is on medications with narrow TIs that are sensitive P-gp or BCRP substrates and are administered orally or on medications classified as strong inhibitors of P-gp or BCRP.

17. Administration of PPIs should be stopped or switched to another ARA 7 days before administration of FHD-286.

18. Subject is requiring clinically significant or increasing doses of systemic steroid therapy or any other systemic immunosuppressive medication. Local or targeted steroid and immunosuppressive therapies are acceptable. Appropriate steroid replacement to manage endocrine toxicities resulting from prior anticancer systemic therapy is permitted.

19. Subject has undergone any prior treatment with a BRG1/BRM inhibitor.

20. Subject is pregnant or breastfeeding or is planning to become pregnant within 1 year of the start of study treatment.

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Foghorn Therapeutics Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Sarah Reilly, MD

Role: STUDY_DIRECTOR

Foghorn Therapeutics

Locations

City of Hope National Medical Center

Duarte, California, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

Countries

United States

References

DiNardo CD, Fathi AT, Kishtagari A, Bhalla KN, Quintas-Cardama A, Reilly SA, Almon C, Patriquin C, Nabhan S, Healy K, Hickman D, Collins MP, Khalil A, Corrigan D, Zhao T, Piel J, Lyons K, Horrigan K, Schuck V, Martin P, Elliott G, Lahr DL, Bosinger M, D'Aco K, Smolen GA, Hentemann M, Loghavi S, Agresta S, Savona MR, Stein EM. A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies. Clin Cancer Res. 2025 Jun 13;31(12):2327-2338. doi: 10.1158/1078-0432.CCR-24-3790.

Reference Type: BACKGROUND

PMID: 40238563 (View on PubMed)

Other Identifiers

FHD-286-C-002

Identifier Type: -

Identifier Source: org_study_id